
BCLI Stock Performance has been on a steady rise over the past year, with a significant increase in value.
The stock's price has fluctuated between $0.05 and $0.10, with an average price of $0.07.
This upward trend suggests a strong potential for future growth, making BCLI a stock worth keeping an eye on.
According to the data, the 52-week high for BCLI stock was $0.10, while the 52-week low was $0.03.
Discover more: Boston Scientific Ticker Symbol
Compliance and Listings
BrainStorm Cell Therapeutics regained compliance with Nasdaq's minimum closing bid price requirement in October 2024, receiving written notice from Nasdaq confirming this.
The company's continued listing on The Nasdaq Capital Market is now subject to maintaining compliance with Nasdaq's listing requirements.
BrainStorm Cell Therapeutics' stock is listed on the NASDAQ exchange under the ticker symbol BCLI.
This regained compliance is a significant development for the company, allowing it to continue trading on the exchange.
A fresh viewpoint: New York Stock Exchange Shares
Financial Performance
The stock performance of BCLI is quite interesting. The previous close was $2.03, with a day range of $1.96 to $2.15.
The market capitalization of BCLI is $11,578,000, and it's listed on the NASDAQ exchange.
Here's a summary of the financial performance of BCLI:
About the Inc Forecast
Brainstorm Cell Therapeutics Inc has been showing a rising tendency since 2003, with the asset price in an uptrend since May 28th of that year. The current price of BCLI is $2.025 as of January 28th, 2025.
Our custom algorithm, based on Deep Learning, predicts a future price of $6.774 for BCLI after a year, which is a 234.53% increase from the current price. This means that if you invested $100 now, your investment may be worth $334.53 on January 28th, 2026.
The forecast for BCLI varies depending on the timeframe, with a predicted decrease of -1.68% in the 14-day forecast, but an increase of 174.89% in the 1-year forecast.
Here's a breakdown of the forecast for BCLI:
Brainstorm Cell Therapeutics Inc has been growing its earnings at a rate of 10.9% per year over the past 5 years, making it a promising investment opportunity.
BCLI Performance
BCLI's stock performance has been a mixed bag over the years. Its current market cap is $11,578,000, and it's listed on the NASDAQ exchange.
On a similar theme: S B I Card Share Price
The stock's previous close was $2.03, with a day range of $1.96 to $2.15. Its year range is a whopping $1 to $11.
In terms of financial performance, BCLI's diluted EPS (TTM) is a negative $3.45, and its revenue and earnings growth have been 0% year-over-year.
Here's a summary of BCLI's share price history:
BCLI's stock has been volatile, with an average weekly movement of 16.9%, which is higher than the biotechs industry average of 11.4%. However, its weekly volatility has been stable over the past year, but is still higher than 75% of US stocks.
In terms of shareholder returns, BCLI underperformed the US Biotechs industry and the US Market over the past year, returning -66.3% and -4.3% respectively, compared to 22.7% for the US Market.
According to our forecast, BCLI's price is predicted to increase by 234.53% to $6.774 after a year, making it a potentially good portfolio addition for the future.
Readers also liked: State Bank of India Stock Quote
Featured Images: pexels.com


